ESR1 and neoplasm: According to the results of our research, which is believed to represent the current situation more accurately, the concordance and discordance rates between the tru-cut biopsy before NACTx and the residual tumor after NACTx were 95.1% vs. 4.9% for ER, 97.1% vs. 2.9% for PR, 96.1% vs. 3.9% for HR, and 89.2% vs. 10.8% for HER2, respectively.